Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

American Journal of Hematology

Volumn 90, Issue 3, 2015, Pages 193-196

  Jabbour, Elias ^a   O'Brien, Susan ^a   Huang, Xuelin ^a   Thomas, Deborah ^a   Rytting, Michael ^a   Sasaki, Koji ^a   Cortes, Jorge ^a   Garcia Manero, Guillermo ^a   Kadia, Tapan ^a   Ravandi, Farhad ^a   Pierce, Sherry ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE DERIVATIVE; FLUDARABINE; INOTUZUMAB OZOGAMICIN; RITUXIMAB; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; BLOOD CELL COUNT; BLOOD SALVAGE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TRANSPLANTATION; CHILD; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DRUG DOSE REDUCTION; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SALVAGE THERAPY; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; FEMALE; GENE TRANSLOCATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; SURVIVAL ANALYSIS; THROMBOCYTE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHOCYTES; MALE; MIDDLE AGED; PLATELET COUNT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 84923071079     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23901     Document Type: Article

References (16)

1. Mathisen MS, Kantarjian H, Thomas D, et al. Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leuk Lymphoma 2013;54:2592-2600.
2. Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2011;52:325-327.
3. Thorson JS, Sievers EL, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: The past, present and future of calicheamicin research. Curr Pharm Des 2000;6:1841-1879.
4. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 2012;13:403-411.
5. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119:2728-2736.
6. Agresti A. Categorical Data Analysis, 2nd ed. Wiley: Hoboken, NJ; 1990.
7. Kaplan EL, Maier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1965;53:457-481.
8. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
9. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568-5574.
10. Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012;120:2032-2041.
11. Topp MS, Goekbuget N, Stein AS, et al. Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). J Clin Oncol 2014;325s:abstract 7005.
12. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944-950.
13. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
14. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: Concepts and strategies. Cancer 2010;116:1165-1176.
15. Jabbour E, O'Brien S, Nitin J, et al. Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients and as salvage therapy for adult with relapse/refractory acute lymphoblastic leukemia. J Clin Oncol 2014;32, Abstract # 7019.
16. O'Brien S, Jabbour E, Thomas D, et al. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome positive acute lymphoblastic leukemia. J Clin Oncol 2014;32, Abstract # 7064.